Targeting Syk in Autoimmune Rheumatic Diseases
MetadataShow full item record
CitationDeng, Guo-Min, Vasileios C. Kyttaris, and George C. Tsokos. 2016. “Targeting Syk in Autoimmune Rheumatic Diseases.” Frontiers in Immunology 7 (1): 78. doi:10.3389/fimmu.2016.00078. http://dx.doi.org/10.3389/fimmu.2016.00078.
AbstractSpleen tyrosine kinase (Syk) is a member of the Src family of non-receptor tyrosine kinases, which associates directly with surface receptors, including B-cell receptor and Fcγ receptor, and is involved in a variety of signal transduction pathways. Rheumatoid arthritis (RA) and systemic lupus erythematosus are autoimmune diseases in which autoantibodies, immune complexes, and autoreactive T cells account for the expression of tissue inflammation and damage. Syk inhibitors efficiently suppress RA in patients albeit in the expression of unwanted side effects, including gastrointestinal effects, hypertension, and neutropenia. Syk inhibitors also inhibit clinical manifestations in lupus-prone mice. Here, we review the evidence that supports the use of Syk inhibitors to treat rheumatic and other autoimmune diseases.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:26318606
- HMS Scholarly Articles 
Contact administrator regarding this item (to report mistakes or request changes)